| Date | Title | Description | |
|---|---|---|---|
| 06 May 2026 | On P&L | The Company releases the press release related to the first three months of 2026 financial results. | Download |
| 06 May 2026 | On P&L | The Company releases the first three months of 2026 financial results presentation. | Download |
| 25 Feb 2026 | On P&L | The Company releases the full year 2025 financial results presentation. | Download |
| 25 Feb 2026 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors. | Download |
| 25 Feb 2026 | On P&L | The Company releases the press release related to the full year 2025 financial results. | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 06 May 2026 | Announcement of general shareholders’ meeting | The Company announces the calling of its 2026 Ordinary General Shareholder´s Meeting. | Download |
| 01 Apr 2026 | On corporate transactions | ROVI announces the closing of the Asset Purchase Agreement entered into in September 2025 for the acquisition of a pharmaceutical manufacturing facility in Phoenix, Arizona (USA) | Download |
| 25 Feb 2026 | Annual Corporate Governance Report | The Company submits the Annual Corporate Governance Report for fiscal year 2025. | Download |
| 25 Feb 2026 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2025 annual report regarding remuneration of the members of the Board of Directors. | Download |
| 18 Nov 2025 | On business and financial situation | The Company releases the press release in relation to the signing of the definitive collaboration agreement with Roche for the manufacture of a new medicine in development | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: modification of transactions conducted from 11 July to 30 September 2017. | Download |
| 03 Oct 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted from 11 July to 30 September 2017 | Download |
| 07 Sep 2017 | Otros sobre negocio y situación financiera | The Company informs that commences the enoxaparin biosimilar marketing in Germany | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |
| 26 Jul 2017 | Información sobre resultados | ROVI releases the presentation related to the 2017 first half results | Download |